Introduction
Anisomycin, as an antiprotozoal agent with antibacterial or antifungal activity, is a pyrrolidine antibiotic originally and the chemical formula is C 14 -H 19 -N-O 4 , designated as 2-p-methoxyphenylmethyl-3-acetoxy-4-hydroxypyrrolidine ( Figure 1A ). Its pyrrolidine ring is important for the translational inhibitory activity of anisomycin. Acetylation of the nitrogen or deacetylation at the 3 ' position inhibits this activity [1] . It can bind with the 60S ribosomal subunit and prevent peptide bond formation to result in block of peptide elongation and degradation of polyribosome, functionally inhibiting synthesis of numerous proteins and DNA [2] . Recent studies show that anisomycin activates c-jun N-terminal kinase/stress-activated protein kinase (JNK) and p38 mitogen activated protein kinase (p38) to protect the neurons of cerebral cortex [3] . Therefore, it is frequently used as an activation agent in mitogenactivated protein kinase signaling pathways. It is also discovered that anisomycin induces macrophage apoptosis in rabbit atherosclerotic plaques through p38 signaling [4] . Our group accidentally found that a quite low-dose anisomycin could dramatically inhibit biological behaviors of primary T lymphocytes [5] . Jurkat T cell line, isolated from the peripheral blood of a patient with acute T cell leukemia, is a tumor cell line derived from human T lymphocytes. Thus, the phenotype and certain biological features of Jurkat T cells are similar to normal T cells. Dissimilarly, the former possesses malignant proliferation properties. We suppose that anisomycin may exert the same influence on human leukemia Jurkat T cells. In this study effect of anisomycin on biological behaviors of Jurkat T cells was observed to explore possibility of anisomycin applied to treating Jurkat T cells in vitro. The results indicate that the suppressive action of anisomycin on Jurkat T cell growth may be related to the inhibition of transforming growth factor-β (TGF-β) and the activation of extracellular regulated kinase 1/2 (ERK1/2), and the apoptosis of Jurkat T cells.
Experimental Procedures

Cell culture
Jurkat T cells, a human T cell lymphoma cell line (China Center for Type Culture Collection, Wu Han University), were cultured in RPMI 1640 medium containing 10% fetal calf serum (GibcoBRL) at 37°C in the presence of 5% CO 2 and the culture was renewed every 2 days for passage.
Colony formation and cell viability
Jurkat T cells at a density of 5×10 5 cell mL -1 were planted into a 96-well plate, and treated with 1.0-160.0 ng mL -1 of anisomycin (Sigma, Saint Louis, Missouri, USA) or medium without anisomycin as a control. The cells were incubated in triplicate at 37°C for 48 h, and then observed for colony formation of Jurkat T cells under a microscope. At the end of stipulated time following anisomycin treatment, 5 mg mL -1 of 3-(4,5-dimethylthia-zol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) (Sigma, Saint Louis, Missouri, USA) was added to each well and the cells were incubated for 4 h. The supernatant was removed and the pellet was dissolved with 100 μl of dimethyl sulphoxide (Sigma, Saint Louis, Missouri, USA) that was added to each well, and then plates were shaken for 10 min at 37°C, keeping in dark place. The absorbance was recorded at 490 nm wavelength on a Microplate Reader (BIO-RAD). Then the optical density (OD) was calculated as follows:
Cell activation
Jurkat T cells at a density of 2.5×10 6 cells/ml were planted into a 96-well plate, and treated with 1.0-160.0 ng mL 
Cell cycle
Jurkat T cells at a density of 2.5×10 6 cell mL
were planted into a 96-well plate, and treated with 10.0-160.0 ng mL -1 of anisomycin, or medium without anisomycin as a control. The cells were incubated at 37°C for 48 h, and then collected in flow tubes. Thereafter they were stained with 400 μL propidium iodide (PI) (KeyGen, Nanjing, China) solution (50 mg L 
Apoptosis
were planted into a 96-well plate, and treated with 10.0-160.0 ng mL -1 of anisomycin at 37°C for 24 h. Apoptosis assay of the cells was performed using an Annexin V/FITC Kit containing propidium iodide (PI) (KeyGEN Biotech, China) according to the manufacturer's instruction and analyzed on a flow cytometer with a Cell-Quest software. Electronic compensation of the instrument was done to exclude overlapping of the emission spectra. Total 10,000 events were acquired and the cells were properly gated for analysis.
ELISA
Jurkat T cells at a density of 5×10 5 cell mL -1 were planted into a 12-well plate, and treated with 10.0-160.0 ng mL 
Western blot
Jurkat T cells at a density of 5×10 5 cell mL -1 were planted into a 12-well plate, and treated with 40.0 ng mL -1 of anisomycin at 37°C for 0, 0.5, 1, 2, 3, 4 and 6 h. The cells were collected and then lysed with radio-immunoprecipitation assay (RIPA) lysis buffer (BioColors, Shanghai, China) containing phenylmethanesulfonyl fluoride. Cytoplasmic protein of the cells was extracted using a Cytoplasmic Protein Extraction Kit (Beyotime, Beijing, China) according to the manufacturer's instruction. Equal protein loading was verified by Bradford protein assay. Then immunoblotting was performed and transferred to nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ, USA) after sodium dodecyl sulfatepolyacrylamide gel electrophoresis (Bio-Rad, Hercules, CA, USA). The membranes were incubated with rabbit anti-ERK1/2 (1:1,000) and anti-phosphorylated ERK1/2 primary antibodies (1:1,000) (Cell Signaling, Danvers, MA, USA) for 2 h at room temperature. Afterwards, the membranes were incubated with a horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody (1:2,000) (Cell Signaling, Danvers, MA, USA) for 1 h at room temperature. The bands were finally visualized by enhanced chemiluminescence (ECL) (Thermo Fisher Scientific, Rockford, IL, USA) according to the manufacturer's instruction. The band density was checked by FluorChem 8000 imaging system with an analysis software (Alpha Innotech, Santa Clara, CA, USA).
Statistical analysis
All the data were analyzed by SPSS 13.0 statistical package. Results were presented as means ± SE. Comparison between sets of two groups was performed using Student's t-test, while sets of more than two groups were compared by one-way ANOVA. Kruskal-Wallis non-parametric ANOVA was used to analyze non-parametric data. Statistical significance was accepted if the null hypothesis was rejected with P<0.05.
Results
Anisomycin inhibits Jurkat T cell colony formation and proliferation
As shown in Figure 2 , the inhibitory rate of the treated Jurkat T cells was increased with the increasing concentrations of anisomycin, appearing in a doserelated relationship. It reached over 70% while anisomycin dose was elevated to 40 ng mL -1 . The number and size of Jurkat T cell cluster were significantly decreased with the increasing concentrations of anisomycin, especially within 20.0−160.0 ng mL -1 . Our results indicated that the colony formation of Jurkat T cells was significantly inhibited with the increasing concentrations of anisomycin. The colony sizes were remarkably reduced while the used dose of anisomycin surpassed 20 ng mL -1 ( Figure 2B ).
Anisomycin represses Jurkat T cell activation
Cell activation is also one of important behavior of cells. To determine impact of anisomycin on Jurkat T cell activation, Jurkat T cells were treated with different concentrations of anisomycin, and CD69 and CD25 levels on Jurkat T cells were characterized by flow cytometry. Compared with the control, the CD69 ( Figure 3A ) and CD25 ( Figure 3B ) expressions were clearly decreased with the enhanced concentrations of anisomycin, but there was no significant difference between the control group and PMA plus ionomycin group, although PMA plus ionomycin is conventionally used as classical stimuli to activate T lymphocytes. Therefore, these data indicate that Jurkat T cells appear in highly activated status without PMA plus ionomycin stimulation but anisomycin dramatically inhibit the earlyand mid-stage activations of Jurkat T cells. 
Anisomycin causes Jurkat T cell cycle arrest
To observe impact of anisomycin on Jurkat T cell cycle, the DNA content for the cells was determined by flow cytometry. As shown in Figure 4 , the percentage of Jurkat T cells at Sub-G1 phase was increased with the augmented concentrations of anisomycin, suggesting the enhancement of the cell apoptosis.
But the percentages of Jurkat T cells at S phase were decreased with the augmenting concentrations of anisomycin ( Figure 4A ). And there were no significant changes in the G0/G1 phase ( Figure 4B ), suggesting ) and medium without anisomycin as a control for 48 h. And then the treated cells were stained for detection of the cell cycle by flow cytometry. B)The results are described in the histogram. These data are representative of three independent experiments. *P<0.05, ** P< 0.01 vs. the control group.
that anisomycin significantly arrests Jurkat T cell cycle at S phase, and induces the cell apoptosis.
Anisomycin induces Jurkat T cell apoptosis
To observe impact of anisomycin on Jurkat T apoptosis, the treated cells were determined for early-and late-stage apoptosis by flow cytometry. Simultaneously, adriamycin that has been proved to be an efficacious drug to Jurkat T tumor was utilized as a positive control. Consistent with the occurrence of the sub-diploids observed above in the cell cycle, anisomycin could promote Jurkat T cell apoptosis, especially the earlystage apoptosis rate enhancement, suggesting that anisomycin induces Jurkat T cell apoptosis ( Figure 5 ). Compared with the adriamycin-treated group, the used dose of anisomycin was much lower than that of adriamycin, but the apoptosis rate induced by anisomycin was higher than that by adriamycin.
Anisomycin reduces production of the cytokines in Jurkat T cells
To further examine effect of anisomycin on the cytokines produced by Jurkat T cells, Jurkat T cells were treated with different concentrations of anisomycin for 24 h. Then the harvested culture supernatants were used to determine the cytokine levels by ELISA. Compared with the control group, the productions of IL-4, IL-10, IL-17, IFN-γ and TGF-β by the treated Jurkat T cells were attenuated with the increasing concentrations of anisomycin, especially IL-4 and IL-17. But except IL-17, the role of adriamycin to inhibit the cytokine production was remarkably weaker than that of anisomycin ). And then the treated cells were stained for flow cytometry analysis.
although the used dose of the former was much higher than that of the latter ( Figure 6 ). The data indicate that anisomycin suppresses cytokine production by the Jurkat T cells. Therefore, the reduction of TGF-β secretion may be related to the inhibition of Jurkat T cell growth by anisomycin.
Anisomycin inhibits the activation of ERK1/2
It is well known that ERK1/2 activation is also intimately related to cell growth except TGF-β. Therefore, nonphosphorylated ERK1/2 (ERK1/2) and phosphorylated ERK1/2 (P-ERK1/2) in the treated Jurkat T cells were tested by Western blot. The expressional level of ERK1/2 was not changed with anisomycin treatment time ( Figure 7A ), or with its exposure dose ( Figure 7C ). However, the expressional level of P-ERK1/2 was obviously decreased with the extension of anisomycin (40 ng mL -1 ) exposure time, reaching its lowest points especially within 4-6 h after the treatment ( Figure 7B) , and also reduced with the increasing doses of anisomycin ranging from 40 to 160 ng mL -1 ( Figure 7D ). On the contrary, adriamycin had no obvious influence on ERK1/2 and P-ERK1/2. The data suggest that anisomycin can repress the activation of ERK1/2 signaling, that is associated with the inhibition of Jurkat T cell growth.
Discussion
Anisomycin, as an antiprotozoal agent with little antibacterial or antifungal activity, is a pyrrolidine antibiotic first isolated from Streptomyces griseolus [2] . It can bind to 60S ribosomal subunit and block peptide bond formation and DNA synthesis. It is described as a potent protein synthesis inhibitor in eukaryotic organisms that is structurally specific and functionally reversible. It has been reported that anisomycin is able to stimulate JNK activation and leads to the apoptosis in oncogenic Ha-Ras positive cells, but not in normal keratinocytes [6] . Moreover, the treatment of the cells with inhibitors ) and adriamycin at the dose of 0.5 µg mL -1 was set as a positive control. Then IL-4, IL-10, IL-17, IFN-γ and TGF-β in the cell culture supernatant were measured using ELISA. These data are representative of three independent experiments. *P<0.05, ** P< 0.01 vs. the control group.
of JNK displays the resistance to anisomycin-induced apoptosis, suggesting that the oncogenic Ha-Ras is important for anisomycin-induced JNK activation and apoptosis in transformed keratinocytes [6] . Croons et al. showed that anisomycin induced macrophage apoptosis in rabbit atherosclerotic plaques through p38 signaling [4] . It was found in our previous study that a quite low dose of anisomycin strikingly inhibited the various biological behaviors of primary T lymphocytes.
Although an administered dose of anisomycin was just 1% of dexamethasone, there existed no difference in the in vitro inhibition of T cell response to allogeneic T cells between them [5] . Therefore, we suppose that this action of anisomycin may be utilized to treat tumor cells. In the current study, Jurkat T cell line was selected to test this possibility as an in vitro tumor model due to its T cell properties. The data showed that the low dose of anisomycin could significantly inhibit the colony formation and proliferation of Jurkat T cells in a doseresponse relationship. And anisomycin could not only block Jurkat T cells into S-phase with the appeared sub-G1 phase, but also repress the activation of Jurkat T cells at early-and mid-phases and promote their apoptosis at early-and late-stages, which was followed by the decreased production of IL-4, IL-10, IL-17, TGF-β and IFN-γ, and the down-regulated expression of phosphorylated-ERK1/2. Moreover, the anisomycin action was stronger than that of adriamycin. The results suggest that anisomycin dramatically inhibits Jurkat T cell proliferation, arrests the cell cycle at S-phase and promotes the apoptosis of Jurkat T cells.
It is well known that activations of JNK and p38 kinases are related to cell proliferation, apoptosis and inflammation [7] [8] [9] . It was found that anisomycin might also activate JNK [10] and p38, possibly influencing cell apoptosis [4, 11] . Thus it is frequently used as an activation agent in mitogenactivated protein kinase signaling pathways. In this study, consistent with the inhibition of Jurkat T cell proliferation, the data demonstrated that 40 ng mL -1 of anisomycin was able to markedly down-regulate the level of phosphorylated-ERK1/2 in Jurkat T cells, leading to the inhibition of ERK1/2 signaling pathway activation. This may be one of important mechanisms for anisomycin to suppress Jurkat T cells. In another aspect, TGF-β is a pleiotropic polypeptide growth factor that mediates the transformation of non-neoplastic rat kidney and murine AKR-2B fibroblasts [12] [13] [14] . It induces growth arrest and apoptosis in epithelial cells via a transmembrane serine/threonine kinase receptor complex [15, 16] . Subsequent studies revealed that TGF-β acted as a tumor suppressor, whereas it exerted pro-oncogenic effects in metastatic tumors [17, 18] . Activated T cells produce cytokines.
For example, Th1 cells secrete IL-2 while Th2 cells produce IL-4 and others [19] . Th17 cells secrete IL-17 while Tr cells produce IL-10 and others [20, 21] . And the high expression of TGF-β can be detected in most tumor cell lines [22, 23] . Our results showed that anisomycin inhibited the production of differently representative cytokines in Jurkat T cells, suggesting that it can inhibit functions of T cell subpopulation. The inhibition of Jurkat T cell growth may be related to the anisomycin-inhibited expression of TGF-β, too. Therefore, it is possible that anisomycin can inhibit Jurkat T cell growth through blocking of TGF-β stimulating signal and ERK1/2 activating signal besides binding to 60S ribosomal subunit to block peptide bond formation. The inhibitory role of anisomycin on Jurkat T cell growth is also related to induction of Jurkat T cell apoptosis by promoting the activation of JNK and p38 signaling pathways. In vivo therapeutic efficacy and detailed mechanic processes remain to be explored.
